Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Trypanosoma brucei | methionyl-tRNA synthetase, putative | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Methionyl-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Schistosoma mansoni | methionine-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | methionyl-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Trypanosoma brucei | methionyl-tRNA synthetase, putative | 0.0066 | 0.5 | 0.5 |
Plasmodium falciparum | methionine--tRNA ligase | 0.0066 | 0.5 | 0.5 |
Trypanosoma cruzi | methionyl-tRNA synthetase, putative | 0.0066 | 0.5 | 0.5 |
Loa Loa (eye worm) | methionyl-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Plasmodium vivax | methionine--tRNA ligase, putative | 0.0066 | 0.5 | 0.5 |
Mycobacterium ulcerans | methionyl-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Echinococcus granulosus | methionine tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Trichomonas vaginalis | methionine-tRNA synthetase, putative | 0.0066 | 0.5 | 0.5 |
Mycobacterium leprae | Probable methionyl-tRNA synthase MetS | 0.0066 | 0.5 | 0.5 |
Leishmania major | methionyl-tRNA synthetase, putative | 0.0066 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Methionyl-tRNA synthetase MetS (MetRS) (methionine--tRNA ligase) | 0.0066 | 0.5 | 0.5 |
Toxoplasma gondii | methionyl-tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Echinococcus multilocularis | methionine tRNA synthetase | 0.0066 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 7.657 uM | PubChem BioAssay. Luminescence-based biochemical high throughput dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS). (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 50 um | PUBCHEM_BIOASSAY: Tumor Hsp90 Inhibitors Dose Response Confirmation. (Class of assay: confirmatory) [Related pubchem assays: 429 (Primary screen preceding this dose response confirmation assay.)] | ChEMBL. | No reference |
IC50 (functional) | 118.556 uM | PubChem BioAssay. Counterscreen Fluorescent Polarization-based biochemical high throughput orthogonal dose response assay for inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.5131 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.